Advertisement

Get Topic Updates

Share

Written by the OrganizedWisdom Team with as the reviewer. All original content is supervised by the The OrganizedWisdom Medical Review Team

americanheart.org

1 of 0

Resource Description:

Merck/Schering-Plough Pharmaceuticals released results from the ENHANCE trial, which found that the ezetimibe/simvastatin (Zetia/Zocor) combination drug known as Vytorin was no more effective in reducing artery plaque build-up than simvastatin (Zocor) alone.

« Back to the Cholesterol Controversy WisdomCard

Related Health Centers:

Advertisement